Improving Outcomes After Marrow Transplant
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
This work aims to find the best ways to prevent serious complications like graft-versus-host disease, infections, and cancer relapse for patients receiving marrow transplants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11168889 on NIH RePORTER |
What this research studies
Patients who undergo marrow transplantation often face challenges such as graft-versus-host disease (GVHD), infections, and the return of their original disease. These complications are interconnected, making them difficult to tackle individually. Our goal is to discover the most effective strategies to prevent GVHD, which could then reduce the need for strong medications that weaken the immune system. By doing so, we hope to lower the risk of infections and help the transplanted cells fight off any remaining cancer, leading to better overall health for patients.
Who could benefit from this research
Good fit: Ideal candidates are patients who are undergoing or have recently undergone a marrow transplant and are at risk for complications like graft-versus-host disease.
Not a fit: Patients who are not undergoing marrow transplantation or are not at risk for its specific complications would not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could significantly improve the safety and effectiveness of marrow transplantation, leading to better long-term health and fewer complications for patients.
How similar studies have performed: Previous advancements in targeting immune cells and using B-cell blockade have shown promise in preventing and treating chronic graft-versus-host disease, but the optimal overall prevention strategy is still being determined.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Gooptu, Mahasweta — Dana-Farber Cancer Inst
- Study coordinator: Gooptu, Mahasweta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.